ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors

NCT05405595 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

186

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced/Metastatic Solid Tumors

Interventions

DRUG: ADG126
DRUG: Pembrolizumab (KEYTRUDA®)
DRUG: Standard of Care (Trifluridine/Tipiracil-Bevacizumab)
DRUG: Standard of care (Fruquintinib)

Sponsor

Adagene Inc

Collaborators

[object Object]